Peptides for weight loss: GLP‑1s vs other peptides people ask about

Peptides for weight loss are a rapidly discussed topic, ranging from well‑studied GLP‑1 receptor agonists to many lesser‑tested compounds sold online as weight loss peptides. This article compares GLP‑1s (and dual agonists) with other peptides people frequently ask about, summarizes the evidence, and covers dosing, biomarkers to monitor (HbA1c, triglycerides, ALT), and safety considerations.

What the evidence shows: strong vs limited data

Clinical trial data support several GLP‑1 receptor agonists and dual incretin agonists for meaningful weight reduction and metabolic benefit. Many other peptides marketed for fat loss have limited human trials or rely on animal and small, uncontrolled studies.

• High‑quality evidence: semaglutide, liraglutide, and tirzepatide have randomized controlled trials showing substantial average weight loss and improvements in metabolic biomarkers.

• Moderate or narrow evidence: tesamorelin has evidence for reducing visceral fat in people with HIV‑associated lipodystrophy but is not a general obesity treatment.

• Limited or experimental: BPC‑157, AOD9604, CJC‑1295, ipamorelin and many over‑the‑counter “fat loss peptides” lack robust clinical data for weight loss in humans.

GLP‑1s and dual agonists: what we know

GLP‑1 receptor agonists and dual GIP/GLP‑1 agonists are the best‑supported peptide therapies for weight management.

Efficacy and biomarkers

Randomized trials have shown:

• Substantial mean weight loss versus placebo with semaglutide (2.4 mg weekly) and tirzepatide (escalating weekly doses).

• Improvements in glycemic control (reduced HbA1c) in people with diabetes or prediabetes.

• Reductions in triglycerides and modest improvements in liver enzymes (ALT) and nonalcoholic fatty liver disease markers in some studies.

These peptides affect appetite, gastric emptying, and glucose metabolism, which in turn influence HbA1c, triglycerides, and ALT.

Dosing and titration (typical labeled regimens)

• Semaglutide (for weight): typically started low and escalated to 2.4 mg subcutaneous once weekly to reduce GI side effects.

• Liraglutide (Saxenda): daily subcutaneous dosing up‑titrated to 3.0 mg per day.

• Tirzepatide (Zepbound for weight; Mounjaro for diabetes): weekly dosing with stepwise increases (e.g., 2.5 mg start, then escalation to 5, 10, 15 mg depending on label and clinical judgment).

Titration schedules vary by product and indication; follow prescribing information and a clinician’s plan to minimize adverse effects.

Common side effects and contraindications

• Most common: nausea, vomiting, constipation or diarrhea, and early satiety.

• Serious but uncommon: pancreatitis, gallbladder disease, and possible increases in heart rate.

• Boxed or labeled cautions: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) is a contraindication for many GLP‑1 RAs.

• Pregnancy: these agents are not recommended in pregnancy or when trying to conceive.

Monitoring typically includes HbA1c (if diabetic), fasting lipids including triglycerides, liver enzymes (ALT), and attention to symptoms of pancreatitis or gallbladder disease.

Other peptides people ask about: evidence and cautions

Tesamorelin

• Approved indication: reduces visceral adipose tissue in HIV‑associated lipodystrophy.

• Evidence: randomized trials in HIV populations show visceral fat reduction; not broadly approved for general obesity.

• Monitoring: IGF‑1, glucose, and liver enzymes where indicated.

Setmelanotide

• Indication: approved for rare genetic forms of obesity (e.g., POMC, LEPR deficiencies).

• Not applicable to common obesity without those genetic diagnoses.

Growth hormone secretagogues (CJC‑1295, ipamorelin) and AOD9604

• Evidence: mostly animal studies or small human studies with mixed results; insufficient evidence for routine weight reduction.

• Risks: unregulated formulations, potential metabolic effects (IGF‑1 changes), and unknown long‑term safety.

BPC‑157 and other experimental peptides

• Evidence: largely preclinical. Human data are sparse or absent.

• Concerns: dosage, purity, sterility, and unmeasured adverse effects.

Comparing GLP‑1s vs other weight loss peptides

• Strength of evidence: GLP‑1s and dual agonists have robust RCT data for weight reduction and metabolic improvements. Most other peptides do not.

• Regulatory status: GLP‑1s (some agents) are FDA‑approved for chronic weight management. Many peptides are unapproved for weight loss and are marketed off‑label or via compounding pharmacies.

• Biomarker effects: GLP‑1s reliably improve HbA1c (in people with dysglycemia), lower triglycerides, and can improve ALT in NAFLD studies. Other peptides rarely show consistent biomarker benefits in humans.

• Safety profile: GLP‑1s have well‑defined common adverse effects and labeled contraindications. Safety data for many other peptides are insufficient.

Sourcing, legal status, and safety concerns

• Approved prescription products: safest when used under clinician supervision with pharmacy dispensing approved formulations.

• Compounded or online peptides: carry risks of contamination, incorrect dosing, and lack of efficacy data. These products are often not FDA‑evaluated.

• Always discuss sourcing with a licensed clinician and prefer regulated products when possible.

Monitoring and important biomarkers to track

Baseline and periodic lab monitoring can improve safety and guide therapy:

• HbA1c: baseline and periodic checks if you have diabetes or for metabolic tracking.

• Fasting lipids, especially triglycerides: many GLP‑1s reduce triglycerides; monitor for changes.

• Liver enzymes (ALT): useful in people with suspected NAFLD or when symptoms suggest hepatic issues.

• Additional tests when indicated: pregnancy test for women of childbearing potential, IGF‑1 if using GH‑related peptides, and pancreatic enzymes if clinically suspected pancreatitis.

Who should avoid or use caution

• Pregnancy or planning pregnancy: avoid GLP‑1s and many experimental peptides.

• Personal or family history of medullary thyroid carcinoma or MEN2: avoid GLP‑1 receptor agonists per labels.

• History of pancreatitis or severe gallbladder disease: use caution and discuss risks with a clinician.

• Unstable psychiatric illness: discuss potential appetite and mood effects with your clinician.

• People using insulin or sulfonylureas: risk of hypoglycemia when combined with glucose‑lowering agents requires dose adjustments and monitoring.

Practical usage considerations

• Start low and titrate slowly for GLP‑1s to reduce GI side effects.

• Expect months of treatment to reach full effect; stopping often leads to weight regain if behavioral supports are not maintained.

• Combine medication with evidence‑based behavioral interventions (nutrition, activity, sleep, stress management) for best results.

• Regular follow‑up allows dose adjustment, monitoring of HbA1c, triglycerides, ALT, and screening for adverse events.

Takeaways

• GLP‑1 receptor agonists and some dual agonists have the strongest, highest‑quality evidence among peptides for weight loss and metabolic benefit.

• Many other peptides marketed as weight loss peptides lack robust human data; safety and efficacy are uncertain.

• Key biomarkers to monitor include HbA1c, triglycerides, and ALT — both to assess benefit and detect potential harms.

• Use only approved, clinician‑supervised therapies when possible; avoid unregulated products sold online.

• Discuss contraindications (thyroid cancer history, pregnancy, pancreatitis) and monitoring plans with your clinician before starting therapy.

Conclusion

Peptides for weight loss are not a single class: GLP‑1s and dual incretin agonists stand out with strong clinical evidence and labeled dosing, while many other peptides remain experimental or unsupported by high‑quality trials. Decisions about therapy should balance potential benefits, biomarker changes (HbA1c, triglycerides, ALT), and known risks, and should be made in partnership with a qualified clinician who can arrange appropriate monitoring.

Join Mito to test 100+ biomarkers and get concierge-level guidance from your care team